Dacisteine

Dacisteine

SCHEMBL2402188

CC(=O)NC(CSC(C)=O)C(=O)O

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.55
KDM4E B2RXH2 1/20 0.55
THRB P10828 1/20 0.55
ALOX15 P16050 1/20 0.55
NFKB1 P19838 1/20 0.55
PTGS2 P35354 1/20 0.55
THPO P40225 1/20 0.55
RECQL P46063 1/20 0.55
BLM P54132 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
ALDH1A1 P00352 2/20 0.53
PSMB11 A5LHX3 1/20 0.43
PSMA7 O14818 1/20 0.43
PSMB1 P20618 1/20 0.43
PSMA1 P25786 1/20 0.43
PSMA2 P25787 1/20 0.43
PSMA3 P25788 1/20 0.43
PSMA4 P25789 1/20 0.43
PSMB8 P28062 1/20 0.43
PSMB9 P28065 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dacisteine SCHEMBL1814125 1.00 MAPT (0.55) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL8918473 0.88 NOD1 (0.49) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL10564990 0.85 MAPT (0.42) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL2403433 0.84 MAPT (0.42) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL12308075 0.84 TGFBR1 (0.43) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL24067699 0.83 MAPT (0.59) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL13921443 0.83 MAPT (0.59) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL6308419 0.83 MAPT (0.59) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL308082 0.83 MAPT (0.59) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL4952983 0.83 MAPT (0.59) MAPTKDM4ETHRBALOX15NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12636311-B2 Topically administered strontium-containing complexes for treating pain, pruritis and inflammation GALLEON LABS LLC (US) 2026-05-26 US claimed
US-20250099498-A1 STRONTIUM BASED COMPOSITIONS AND FORMULATIONS FOR PAIN, PRURITUS, AND INFLAMMATION GALLEON LABS LLC (US) 2025-03-27 US claimed
US-12121536-B2 Strontium based compositions and formulations for pain, pruritus, and inflammation GALLEON LABS LLC (US) 2024-10-22 US claimed
US-20240041919-A1 TOPICALLY ADMINISTERED STRONTIUM-CONTAINING COMPLEXES FOR TREATING PAIN, PRURITIS AND INFLAMMATION GALLEON LABS LLC 2024-02-08 US claimed
US-20220323485-A1 STRONTIUM BASED COMPOSITIONS AND FORMULATIONS FOR PAIN, PRURITUS, AND INFLAMMATION PIKE, JOSEPH D. 2022-10-13 US claimed
EP-2827847-B1 TOPICALLY ADMINISTERED STRONTIUM-CONTAINING COMPLEXES FOR TREATING PAIN, PRURITIS AND INFLAMMATION GALLEON LABS LLC (US) 2022-09-14 EP claimed
EP-3284462-B1 STRONTIUM BASED COMPOSITIONS AND FORMULATIONS FOR PAIN, PRURITUS, AND INFLAMMATION GALLEON LABS LLC (US) 2022-08-03 EP claimed
US-11235002-B2 Strontium based compositions and formulations for pain, pruritus, and inflammation GALLEON LABS LLC (US) 2022-02-01 US claimed
US-20210177888-A1 TOPICALLY ADMINISTERED STRONTIUM-CONTAINING COMPLEXES FOR TREATING PAIN, PRURITIS AND INFLAMMATION JOSEPH D. PIKE 2021-06-17 US claimed
US-20190269720-A1 STRONTIUM BASED COMPOSITIONS AND FORMULATIONS FOR PAIN, PRURITUS, AND INFLAMMATION PIKE, JOSEPH D. 2019-09-05 US claimed
US-20030158118-A1 Combination of cimetidine and cysteine derivatives for treating cancer WEIDNER MORTEN SLOTH (DK) 2003-08-21 US claimed
WO-2003045359-A2 COMBINATION OF CIMETIDINE AND CYSTEINE DERIVATIVES FOR TREATING CANCER ASTION ONCOLOGY APS (DK) 2003-06-05 WO claimed
US-20030095959-A1 Topical skin composition ACCESS BUSINESS GROUP INTERNATIONAL LLC. 2003-05-22 US claimed
WO-2003002125-A2 COMBINATION OF AMINOSUGARS AND CYSTEINE OR CYSTEINE DERIVATIVES ASTION A/S (DK) 2003-01-09 WO claimed
EP-1231886-A1 TOPICAL SKIN COMPOSITION Alticor Inc. (US) 2002-08-21 EP claimed
WO-2001037788-A1 TOPICAL SKIN COMPOSITION ALTICOR INC. (US) 2001-05-31 WO claimed
EP-0716601-B1 USE OF N,S-DIACETYLCYSTEINE-ETHYLESTER (DACEE) FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF VIRAL DISEASES LUDWIG WEISS DR (DE) 2000-06-28 EP claimed
US-5728373-A EXHIBITING DEEP SKIN PENETRATION BEIERSDORF AG (DE) 1998-03-17 US claimed
EP-0656774-B1 COSMETIC AND DERMATOLOGICAL SUNSCREEN COMPOSITIONS CONTAINING THIOLS AND/OR THIOL DERIVATES BEIERSDORF AG (DE) 1997-01-22 EP claimed
US-4405638-A ANTITUSSIVE AGENTS; ANTIINFLAMMATORY AGENTS; RESPIRATORY SYSTEM DISORDERS SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A (IT) 1983-09-20 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158118-A1 Combination of cimetidine and cysteine derivatives for treating cancer MGMT, CMA1, CYSLTR2 MAPT 4793/4885KDM4E 2224/4885THRB 4256/4885
US-12636311-B2 Topically administered strontium-containing complexes for treating pain, pruritis and inflammation SUCNR1, TRPV1, TRPV2 MAPT 1603/4885KDM4E 1637/4885THRB 3354/4885
US-20030095959-A1 Topical skin composition CUTA, S100A4, KRT18 MAPT 1787/4885KDM4E 4634/4885THRB 3415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.